Global Laboratory Landscape Data and Strategy for Targeted Therapy Launches: Understanding CDx Intelligence and Trends - Diaceutics

Global Laboratory Landscape Data and Strategy for Targeted Therapy Launches: Understanding CDx Intelligence and Trends

May 10th, 2016

Ryan Keeling
Jordan Clark

Will you be launching a targeted therapy in the next 24 to 48 months? This Labceutics webinar provides key insights into laboratory strategy, data and key market landscape differences when planning for a targeted therapy launch.

Join an expert panel of targeted therapy and laboratory data experts to hear about the ‘forgotten’ but critical stakeholder in successful global targeted therapy launches – the molecular laboratory.

Listen to this webinar to learn:

  • How the laboratory landscape and testing environment impacts therapy launches globally
  • Laboratory Mapping and optimal lab footprints based on a therapy, a test and target prescribers
  • The types of biomarker testing being done on a regional basis
  • Key testing measurement criteria about laboratories you need to know
  • Challenges and opportunities in developing regional lab networks to support quality testing

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

October 21st, 2019
Pharma Precision Medicine Readiness Report 2019
March 16th, 2018
PM Readiness Report 2018 Summary
View all reports


June 25th, 2019
FLT3 testing in relapsed Acute Myeloid Leukemia setting is becoming increasingly common, but laboratory turnaround times (TAT) may be a barrier to treatment with second generation FLT3 inhibitors
The treatment landscape in AML has developed at an astonishing pace in the last 3 years, with 5 therapies being approved by the FDA. FLT3 inhibitors gilteritinib (Gil) and quizartinib (Quiz) present an unprecedented opportunity for improved surviv...
May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
View all publications